11 May 2022

DeepMatter Group Plc

DeepMatter extends licensing and collaboration agreement with Standigm

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", "the Group"), the digital chemistry data and software company, has signed a second multi-year licensing and collaboration agreement with Standigm Inc. ("Standigm"), a leading workflow artificial intelligence (AI) drug discovery company, based in South Korea with an increasing international footprint. 

The second agreement is expected to generate revenues for DeepMatter of £280,000.  DeepMatter's first licensing agreement with Standigm was announced on 1 March 2022.

Following the successful deployment of DeepMatter's unique data and laboratory integration platform earlier this year, the agreement includes licensing for DeepMatter's proprietary chemical structure and reaction data and machine-learning Retrosynthesis Software. DeepMatter and Standigm will collaborate to develop further AI-driven drug discovery capabilities, drawing upon the Group's deep digital chemistry expertise.

Jinhan Kim, co-founder and CEO of Standigm:

"As a front-runner in AI drug discovery industry, we have constantly adopted new approaches and technologies without hesitation, to make AI standard in the pharmaceutical industry. In the same vein, we took an early lead in digitalisation of chemistry, which will dramatically reduce the labour needed to make new compounds and broaden accessible chemical space.

"We are delighted to be continuing our long-term relationship with DeepMatter, uniquely strengthening Standigm's workflow artificial intelligence (AI) drug discovery capability with their digital chemistry platforms."

Mark Warne, CEO of DeepMatter, commented:

"This second agreement with Standigm this year demonstrates our unique portfolio capabilities and also deepens the collaboration between our two businesses."

Hanjo Kim, SVP of Global Strategy, Standigm commented:

"We believe that this systemic innovation in chemistry from adopting DeepMatter's platforms will facilitate Standigm's drug discovery research, by stimulating ideas for alternative or novel synthetic routes that otherwise may not be considered.  DeepMatter's capabilities are now an essential component of this offering."

For more information contact

DeepMatter Group Plc
Fraser Benson, Chief Financial Officer                                                                                     0141 548 8156

Canaccord Genuity Limited (Nominated Adviser and Broker)                                     020 7523 8000
Bobbie Hilliam

Meare Consulting                                                                                                                           07990 858548
Adrian Duffield

Standigm Inc.
Sang Ah Lee                                                                                                                sangah.lee@standigm.com

About DeepMatter Group plc 

DeepMatter's SmartChemistry™ platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.  

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

DeepMatter's SmartChemistry™ platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

Visit: www.deepmatter.io and follow @deepmattergroup

Standigm is a workflow AI-driven drug discovery company headquartered in Seoul, South Korea, with subsidiaries in Cambridge, UK, and Cambridge, MA, USA. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines.

Founded in 2015, Standigm has established an early-stage drug discovery workflow AI to generate multiple First-in-Class compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow. The automation effort has expanded to the whole drug discovery process based on Standigm AI platforms, including Standigm ASK™ for novel target discovery and Standigm BEST™ for novel compounds generation.

Standigm has prestigious investors, including SK Holdings, SK Chemicals and Pavilion Capital.

Learn more at http://www.standigm.com.